Asia Pacific Insulin Delivery Devices Market Size & Share 2025 – 2034

Asia Pacific Insulin Delivery Devices Market Size

The Asia Pacific insulin delivery devices market was valued at USD 5.5 billion in 2024. The market is expected to grow from USD 6.1 billion in 2025 to USD 15 billion in 2034, at a CAGR of 10.6% during the forecast period, according to the latest report published by Global Market Insights Inc.

The Asia Pacific insulin delivery device market is witnessing robust growth, stimulated by the rising prevalence of diabetes across the Asia Pacific region, technological advancements in insulin delivery devices, increasing diabetes care expenditure, growing awareness and regional health initiatives. Leading companies such as Novo Nordisk, Medtronic, Sanofi, Eli Lilly and Company, and Becton, Dickinson and Company are at the forefront of this industry. These players maintain their competitive edge through continuous innovation in device technology, strategic partnerships, and strong global distribution networks, all aimed at improving patient outcomes and simplifying diabetes management.
 

The Asia Pacific insulin delivery devices market grew from USD 4.1 billion in 2021 to USD 4.9 billion in 2023, driven by the rising diabetes prevalence, increasing awareness regarding diabetes, and regional health initiatives. Programs such as the Colombo Call to Action by the WHO South-East Asia Region are playing a catalytic role in shaping the market trends. This initiative, endorsed by the member countries, is designed to strengthen diabetes care. Growing efforts in screening, diagnosis, and treatment across the region are propelling the demand for easy-to-use, affordable insulin delivery devices such as pens, pumps, and smart systems. Thus, these initiatives make the market more dynamic and expand access to a broader population.
 

Moreover, the rising prevalence of diabetes in the Asia Pacific region is contributing significantly to the growth of the insulin delivery devices market. For instance, according to the International Diabetes Federation (IDF), the Western Pacific Region, which includes countries such as China, Japan, Australia, among other countries, had 215 million adults living with diabetes in 2024, accounting for 37% of the global diabetic population. Also, in South-East Asia, diabetes prevalence is projected to increase by 73% by 2050, with over 106 million adults affected as of 2024. Thus, the growing burden of diabetes is accelerating the demand for advanced and efficient insulin delivery devices across the Asia Pacific region for managing diabetes.
 

Insulin delivery devices are specialized medical tools used to administer insulin safely, accurately, and conveniently for individuals with diabetes. These devices are essential for effective diabetes management, helping patients regulate their blood sugar levels when their bodies cannot produce enough insulin on their own.

Asia Pacific Insulin Delivery Devices Market Trends

• Technological advancements are reshaping the insulin delivery devices industry, making diabetes management more precise, user-friendly, and connected. Innovations such as smart insulin pens, tubeless pumps, and app-integrated systems are enabling patients to monitor and adjust their insulin doses with greater accuracy and convenience.
   
• These devices often feature Bluetooth connectivity, dose tracking, and reminders, which help improve adherence and reduce the risk of complications associated with inconsistent insulin use. For instance, NovoPen 6 by Novo Nordisk is a smart insulin pen that enhances diabetes management by automatically recording the time and amount of the last doses. It features near field communication, allowing it to sync seamlessly with compatible diabetes management apps for real-time tracking and data sharing, helping users and healthcare providers monitor insulin usage more effectively.
   
• Moreover, increasing diabetes care expenditure is directly fueling the growth of the Asia Pacific insulin delivery devices market. Across Asia, governments are allocating larger portions of healthcare budgets to tackle the growing diabetes burden, funding programs that expand access to insulin, subsidize advanced delivery devices, and strengthen primary care infrastructure. For instance, according to International Diabetes Federation, expenditure on diabetes care in the Western Pacific summed USD 246 billion in 2024, representing 24% of global diabetes-related healthcare spending.
   
• Thus, this surge in expenditure is enabling broader adoption of user-friendly and technologically advanced insulin delivery systems such as smart insulin pens, which is estimated to reach USD 1.9 billion by 2032, pumps, and automated insulin delivery platforms, thereby fostering market growth.
   

Asia Pacific Insulin Delivery Devices Market Analysis

Based on product, the market is divided into devices and consumables. The devices segment accounted for 73.5% of the market share in 2024, primarily due to their technological advancement, long-term usability, and growing preference among patients and healthcare providers. The segment is expected to reach USD 11 billion by 2034, growing with the fastest CAGR of 10.6% during the forecast period. On the other hand, consumables’ segment is expected to grow with slightly higher CAGR of 10.7%. The growth of this segment is primarily stimulated by the recurring demand for essential components such as testing strips, pen needles, syringes, and insulin pumps consumables.
 

• Insulin delivery devices are designed to administer insulin to individuals with diabetes in a safe, accurate, and convenient manner. These include insulin pens and pumps. They vary in complexity from manual devices to smart, automated systems integrated with digital health platforms.
   
• Innovations such as smart pens and closed-loop systems reduce the burden of manual dosing and offer real-time glucose-responsive insulin delivery. As awareness of diabetes increases and healthcare systems invest in home-based care, the demand for efficient and user-friendly delivery solutions continues to rise, especially in regions with high diabetes prevalence.
   
• One such notable example is Omnipod 5 by Insulet, it is a tubeless, wearable insulin pump that integrates with a continuous glucose monitor (CGM) to form a closed-loop system. The device automatically adjusts insulin delivery based on real-time glucose readings, offering users greater freedom and flexibility without the need for daily injections or tubing.
   
• Thus, the devices segment is evolving rapidly, fuelled by technological innovation, rising diabetes care expenditure, and regional health initiatives.
   

Learn more about the key segments shaping this market

Download Free PDF

Based on end use, insulin delivery devices market is classified into hospitals and clinics, home care, and other end users. The home care segment dominated the market in 2024 and is expected to reach USD 7.5 billion by 2034.
 

• The home care segment refers to insulin delivery solutions designed for use outside clinical settings, enabling patients to manage diabetes independently at home. This includes devices such as insulin pens, patch pumps, smart insulin systems, and app-integrated platforms that simplify dosing and monitoring.
   
• Patients are increasingly opting for portable and easy-to-use insulin delivery devices that simplify daily administration and reduce the need for frequent hospital visits. Devices such as disposable insulin pens and wearable pumps are particularly popular in-home settings due to their convenience, minimal training requirements, and reliable performance.
   
• For instance, Admelog SoloStar by Sanofi is a disposable - prefilled insulin pen designed for easy and accurate delivery of rapid-acting insulin. Its key features include a ready-to-use format, eliminating the need for cartridge replacement, and a dial-a-dose mechanism that allows precise dosing in 1-unit increments. The pen is lightweight, discreet, and ideal for mealtime insulin administration, making it a convenient option for patients managing diabetes at home care settings.
   
• Therefore, as demand for remote monitoring and management of diabetes at home is increasing, significant growth can be seen in Asia Pacific market.
   

The China insulin delivery devices market was valued at USD 948 million and USD 1.03 billion in 2021 and 2022, respectively. The market size reached USD 1.25 billion in 2024, growing from USD 1.12 billion in 2023.
 

• The China market is stimulated by a high diabetes burden and strong institutional infrastructure for chronic disease management. As one of the 37 countries and territories in the IDF Western Pacific Region, China plays a dominant role in shaping regional diabetes trends.
   
• In 2024, China had a total adult population of over 1.07 billion, with a diabetes prevalence of 11.9%, amounting to nearly 148 million adults living with diabetes. This makes China is one of the largest diabetes populations globally, and a key market for insulin delivery solutions.
   
• Moreover, government initiatives such as the Healthy China 2030 Plan and the National Essential Medicine System are actively promoting diabetes awareness, early diagnosis, and access to essential treatments, thereby fostering the market growth in the region.
   

Japan insulin delivery devices market accounted for USD 1.1 billion in 2024 and is anticipated to show lucrative growth over the forecast period.
 

• Japan stands out as a critical region in the Asia Pacific market, driven by its advanced healthcare infrastructure, strong regulatory frameworks, and growing burden of diabetes. According to the International Diabetes Federation, as of 2024, Japan had approximately 8.97 million adults living with diabetes, representing an 8.1% prevalence among the total adult population aged 20–79.
   
• Moreover, Japan’s growing aging population is further fueling the growth of this market. This demographic group is more prone to suffer from chronic diseases such as diabetes. For instance, as of September 2024, the number of people aged 65 and older reached 36.25 million, accounting for 29.3% of the total population, the highest aging rate among all countries globally.
   
• Additionally, the country’s emphasis on precision medicine, data-driven care, and patient-centric solutions aligns with the evolving needs of diabetic patients, especially those requiring long-term insulin therapy, thereby propelling the market growth in the country.
   

India insulin delivery devices market is estimated to grow with a significant CAGR of 11.1% through 2034, in the Asia Pacific market.
 

• India is rapidly becoming one of the most dynamic markets within the Asia Pacific insulin delivery devices landscape, fueled by its large diabetic population, rising healthcare spending, and increasing public awareness around diabetes care.
   
• With approximately 101 million individuals living with Type 2 Diabetes Mellitus, India ranked second globally in terms of prevalence, as per the 2025 study published in the Lancet journal. This growing health challenge is driving strong demand for accessible and effective insulin delivery solutions, particularly in urban and semi-urban regions, where lifestyle changes and better healthcare access are accelerating adoption.
   

Australia insulin delivery devices market, exhibiting remarkable growth during the analysis period.
 

• Government-led diabetes programs across Australia are expanding access to care and driving demand for modern insulin delivery solutions. By promoting early diagnosis, education, and affordability, these initiatives are reshaping the market toward more inclusive and technology-driven growth.
   
• The National Diabetes Services Scheme (NDSS), funded by the Australian Government and managed by Diabetes Australia, plays a key role in expanding the insulin delivery devices market across the country.
   
• By offering subsidized access to insulin pens, pumps, and related consumables, NDSS improves affordability and encourages widespread adoption of modern delivery systems. Its emphasis on patient education drives better treatment adherence, in turn increasing demand for user-friendly and technologically advanced devices, propelling market growth.
   

South Korea insulin delivery devices market to experience substantial growth across the Asia Pacific market in 2024.
 

• South Korea’s insulin delivery devices industry is experiencing steady growth, driven by a combination of demographic shifts, rising diabetes prevalence, and strong healthcare infrastructure.
   
• The country has a rapidly growing diabetic population, with older adults more likely to develop Type 2 diabetes and require long-term insulin therapy. For instance, according to the data from International Diabetes Federation, as of 2024, South Korea had approximately 5 million adults aged 20–79 living with diabetes, making it the fifth highest in the Western Pacific region.
   
• Additionally, government initiatives and reimbursement policies are supporting the adoption of advanced insulin delivery systems in both hospital and home care settings, making the market more dynamic and accessible to a broader population.
   

Asia Pacific Insulin Delivery Devices Market Share

• Leading top 5 players in the Asia Pacific insulin delivery devices industry, such as Novo Nordisk, Medtronic, Sanofi, Eli Lilly and Company, and Becton, Dickinson and Company, collectively hold market share of 48%. They are maintaining their dominance through a combination of strategic innovation, regional partnerships, and tailored product offerings.
   
• These companies are leveraging the growing demand for user-friendly, accurate, and minimally invasive insulin delivery systems, including smart insulin pens, CGM-integrated pumps, and jet injectors.
   
• Innovation is central to leadership in this market. Companies are investing heavily in digital health integration, AI-powered monitoring, and remote care solutions. Medtronic’s launch of the MiniMed 780G system in India exemplifies this trend, offering closed-loop insulin delivery for better glucose management.
   
• Additionally, policy reforms and expanded insurance coverage in countries are facilitating broader access to advanced devices, while local manufacturers in India and China are entering the market with cost-effective solutions tailored to regional needs. This dynamic blend of global expertise and localized innovation is reshaping the competitive landscape and ensuring sustained leadership in the Asia-Pacific market.
   

Asia Pacific Insulin Delivery Devices Market Companies

Prominent players operating in the Asia Pacific insulin delivery devices industry are as mentioned below:

• B. Braun Melsungen
• Becton, Dickinson and Company
• Biocon
• Eli Lilly & Company
• F. Hoffmann-La Roche
• Gan & Lee Pharmaceuticals
• Haselmeier
• Insulet
• Medtronic
• Nipro
• Novo Nordisk
• Sanofi
• Suzhou Peng Ye Medical Devices
• Terumo
• Tonghua Dongbao Pharmaceutical
• Wockhardt
   
• Novo Nordisk

Novo Nordisk stands out in the Asia Pacific insulin delivery landscape through its deep-rooted expertise in diabetes care and its commitment to patient-centric innovation. The company offers a comprehensive range of insulin pens, which are known for their ease of use, precision dosing, and ergonomic design.
 

• Medtronic

Medtronic is a prominent player in the Asia Pacific delivery devices market, known for its deep expertise in diabetes care and advanced medical technologies. The company’s strong regional footprint, commitment to innovation, and focus on integrated care solutions have positioned it as a key provider of reliable and effective insulin delivery systems. Through strategic collaborations and technology-driven initiatives, Medtronic continues to enhance access and improve patient outcomes across diverse healthcare landscapes in Asia Pacific.
 

• Insulet

Insulet is emerging as a key innovator in the Asia Pacific insulin delivery devices market, driven by its pioneering tubeless insulin pump technology. The company’s flagship product, the Omnipod system, offers a discreet, user-friendly alternative to traditional insulin delivery methods, significantly improving patient comfort and adherence. Insulet’s strategic collaborations, such as its partnership with Abbott to integrate continuous glucose monitoring with automated insulin delivery, underscore its commitment to personalized diabetes care.
 

Asia Pacific Insulin Delivery Devices Industry News

• In March 2025, Insulet announced the launch of its groundbreaking Omnipod 5 Automated Insulin Delivery (AID) System in Australia, with plans to expand to three additional countries soon. This product launch is set to enhance the lives of thousands of people living with diabetes globally and strengthen the company’s competitive position in the market.
   
• In March 2022, Medtronic India launched the MiniMed 780G system in India, a next-generation closed-loop insulin pump designed for individuals aged 7 to 80 living with type 1 diabetes. Powered by Medtronic’s advanced SmartGuard technology, the system automates the delivery of basal insulin and correction boluses every five minutes. This product launch significantly strengthened the company’s presence in the Indian market.
   

The Asia Pacific insulin delivery devices market research report includes in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million from 2021 - 2034 for the following segments:

Click here to Buy Section of this Report

Market, By Product

• Devices
  • Insulin pumps
    • Tubed pumps
    • Tubeless pumps
  • Pens
    • Reusable
    • Disposable
  • Other insulin delivery devices
• Consumables   
  • Testing strips
  • Pen needles
    • Standard
    • Safety
  • Syringes
  • Insulin pumps consumables

Market, By End Use

• Hospitals and clinics
• Home care
• Other End Use

The above information is provided for the following countries:

• China
• Japan
• India
• Australia
• South Korea
• Taiwan
• Indonesia
• Vietnam